免疫毒の世界市場レポート 2025年

免疫毒市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR9.0％で939億3,000万米ドルに成長します。予測期間の成長は、がん罹患率の増加、天然・オーガニック製品に対する需要の高まり、化粧品産業の拡大、研究開発資金の拡大、ヘルスケアインフラの改善などに起因すると考えられます。予測期間における主な動向としては、精密医療へのアプローチ、ターゲティング戦略の強化、多機能免疫毒素、併用療法、モノクローナル抗体技術の進歩などが挙げられます。

乳がん罹患率の上昇が免疫毒市場の成長を牽引すると予想されます。乳がんは、乳房細胞で開発されるがんの一種であるが、検診の改善、ライフスタイルの変化、平均寿命の伸びなどの要因により、より一般的になりつつあります。免疫毒素は、健康な細胞を温存しながらがん細胞を特異的に標的にして死滅させることにより、従来の化学療法によく見られる副作用を軽減し、乳がん治療を支援します。例えば、米国の非営利団体である米国がん協会によると、2023年に報告された乳がんの新規症例数は300,590例で、2022年の290,560例から増加しています。このように、乳がんの罹患率の上昇が免疫毒市場の拡大に拍車をかけています。

免疫毒市場の主要企業は、がん治療の精度と有効性を向上させるため、抗体薬物複合体（ADC）の開発に注力しています。ADCは標的がん治療用に設計されたバイオ医薬品で、細胞傷害性薬剤に結合した抗体からなり、特定の抗原を発現するがん細胞に薬剤を標的デリバリーすることができます。例えば、2024年4月、米国の製薬会社ファイザーとデンマークのバイオテクノロジー企業Genmab A/Sは、転移性または再発性の子宮頸がん患者を治療するためにデザインされた抗体薬物複合体TIVDAKの米国食品医薬品局（FDA）の完全承認を取得しました。TIVDAKの毒性ペイロードであるモノメチルアウリスタチンEは、細胞死を誘導する微小管破壊剤です。この新しいメカニズムが、がん治療におけるTIVDAKの有効性に寄与しています。TIVDAKは全生存期間において統計学的に有意な改善を示し、再発・転移性子宮頸がん患者にとって有望な選択肢となりました。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界免疫毒PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の免疫毒市場：成長率分析
• 世界の免疫毒市場の実績：規模と成長, 2019-2024
• 世界の免疫毒市場の予測：規模と成長, 2024-2029, 2034F
• 世界免疫毒総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の免疫毒市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 炭疽菌由来の毒素
• ジフテリア毒素（DT）とその誘導体
• シュードモナス外毒素（PE）および誘導体
• リボソーム不活性化タンパク質に基づく免疫毒素
• リボヌクレアーゼベースの免疫毒素
• その他のタイプ
• 世界の免疫毒市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 固形腫瘍
• 白血病
• その他の用途
• 世界の免疫毒市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院と診療所
• がん・放射線治療センター
• 調査室
• その他のエンドユーザー
• 世界の免疫毒市場炭疽菌由来毒素の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 炭疽菌致死毒素
• 炭疽菌防御抗原
• 世界の免疫毒市場ジフテリア毒素（DT）および誘導体の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ジフテリア毒素
• DTフラグメントベースの免疫毒素
• 世界の免疫毒市場シュードモナス外毒素（PE）および誘導体の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• PE38ベースの免疫毒素
• PEベースの融合タンパク質
• 世界の免疫毒市場リボソーム不活性化タンパク質をベースとした免疫毒素の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• リシンベースの免疫毒素
• ゲロニンベースの免疫毒素
• 世界の免疫毒市場リボヌクレアーゼベースの免疫毒素の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• オンコナーゼベースの免疫毒素
• ビナーゼベースの免疫毒素
• 世界の免疫毒市場、その他のタイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 志賀毒素ベースの免疫毒素
• その他の毒素ベースの免疫毒素

第7章 地域別・国別分析

• 世界の免疫毒市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の免疫毒市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 免疫毒市場：競合情勢
• 免疫毒市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Bristol Myers Squibb Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Thermo Fisher Scientific Inc.
• AstraZeneca plc
• Merck KGaA
• BioNTech SE
• Ipsen Pharma
• Seagen Inc.
• Orion Corporation
• GenScript
• Cytek Biosciences
• MacroGenics Inc.
• Sutro Biopharma Inc.
• Sorrento Therapeutics Inc.
• Innate Pharma Inc.
• Cayman Chemical
• ImmunoGen Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 免疫毒市場2029：新たな機会を提供する国
• 免疫毒市場2029：新たな機会を提供するセグメント
• 免疫毒市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Immunotoxins are bioengineered proteins that combine an antibody or antibody fragment with a toxin to specifically target and destroy certain cells, such as cancer cells. The antibody segment of the immunotoxin attaches to a specific antigen on the surface of the target cell, delivering the toxin directly to it. Immunotoxins are crafted to avoid harming healthy cells and tissues, thereby reducing side effects compared to traditional chemotherapy.

The primary types of immunotoxins include anthrax-based toxins, diphtheria toxin (DT) and its derivatives, pseudomonas exotoxin (PE) and its derivatives, ribosome-inactivating protein-based immunotoxins, ribonuclease-based immunotoxins, among others. Anthrax-based toxins are substances produced by the bacteria that cause anthrax, a severe disease. These toxins are used in various applications, including the treatment of solid tumors, leukemias, and more, by different end users such as hospitals and clinics, cancer and radiation therapy centers, research laboratories, and others.

The immunotoxins market research report is one of a series of new reports from The Business Research Company that provides immunotoxins market statistics, including the immunotoxins industry global market size, regional shares, competitors with immunotoxins market share, detailed immunotoxins market segments, market trends, and opportunities, and any further data you may need to thrive in the immunotoxins industry. These immunotoxins market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The immunotoxin market size has grown strongly in recent years. It will grow from $60.97 billion in 2024 to $66.62 billion in 2025 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to the discovery of target antigens, advancements in monoclonal antibody technology, preclinical efficacy studies, clinical trials and regulatory approval, and identification of resistance mechanisms.

The immunotoxin market size is expected to see strong growth in the next few years. It will grow to $93.93 billion in 2029 at a compound annual growth rate (CAGR) of 9.0%. The growth in the forecast period can be attributed to the increasing incidence of cancer, rising demand for natural and organic products, expansion of the cosmetic industry, expansion of R and D financing, and improving healthcare infrastructure. Major trends in the forecast period include precision medicine approach, enhanced targeting strategies, multifunctional immunotoxins, combination therapies, and advancements in monoclonal antibody technology.

The rising incidence of breast cancer is anticipated to drive the growth of the immunotoxin market. Breast cancer, a type of cancer that develops in breast cells, is becoming more common due to factors such as improved screening, lifestyle changes, and increased life expectancy. Immunotoxins assist in breast cancer treatment by specifically targeting and killing cancer cells while sparing healthy cells, thereby reducing the side effects commonly associated with traditional chemotherapy. For example, according to the American Cancer Society, a US-based non-profit organization, there were 300,590 new cases of breast cancer reported in 2023, an increase from the 290,560 cases reported in 2022. Thus, the rising incidence of breast cancer is fueling the expansion of the immunotoxin market.

Leading companies in the immunotoxin market are concentrating on developing antibody-drug conjugates (ADCs) to improve the precision and effectiveness of cancer treatments. ADCs are biopharmaceuticals designed for targeted cancer therapy, consisting of an antibody linked to a cytotoxic drug, which allows for the targeted delivery of the drug to cancer cells expressing a specific antigen. For instance, in April 2024, Pfizer Inc., a US-based pharmaceutical company, and Genmab A/S, a Denmark-based biotechnology company, received full U.S. Food and Drug Administration (FDA) approval for TIVDAK, an antibody-drug conjugate designed to treat patients with metastatic or recurrent cervical cancer. TIVDAK's toxic payload, monomethyl auristatin E, is a microtubule-disrupting agent that induces cell death. This novel mechanism contributes to its effectiveness in cancer treatment. TIVDAK demonstrated statistically significant improvements in overall survival, making it a promising option for patients with recurrent or metastatic cervical cancer.

In February 2024, AbbVie, a US-based biopharmaceutical company, acquired ImmunoGen, Inc. for an undisclosed amount. Through this acquisition, AbbVie seeks to strengthen its oncology portfolio by incorporating ImmunoGen's cutting-edge antibody-drug conjugate technology, thus advancing the development of targeted cancer therapies. ImmunoGen, Inc. is a biotechnology company specializing in immunotoxins.

Major companies operating in the immunotoxin market are Pfizer Inc., Roche Holding AG, AbbVie Inc., Bayer AG, Bristol Myers Squibb, Thermo Fisher Scientific Inc., AstraZeneca plc, Merck KGaA, BioNTech SE, Ipsen Pharma, Seagen Inc., Orion Corporation, GenScript, Cytek Biosciences, MacroGenics Inc., Sutro Biopharma Inc., Sorrento Therapeutics Inc., Innate Pharma Inc., Cayman Chemical, ImmunoGen Inc., Mersana Therapeutics, Molecular Templates Inc., Celldex Therapeutics, CytImmune Sciences Inc., Enzo Life Sciences Inc.

North America was the largest region in the immunotoxin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immunotoxin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the immunotoxin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The immunotoxin market consists of sales of linker molecules, expression systems, antibody or antibody fragments, and cytotoxic agents. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Immunotoxin Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on immunotoxin market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for immunotoxin ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The immunotoxin market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Anthrax Based Toxins; Diphtheria Toxin (DT) And Derivatives; Pseudomonas Exotoxin (PE) And Derivatives; Ribosome Inactivating Proteins Based Immunotoxins; Ribonucleases-Based Immunotoxins; Other Types
• 2) By Application: Solid Tumors; Leukemias; Other Applications
• 3) By End User: Hospitals And Clinics; Cancer And Radiation Therapy Centers; Research Labs; Other End-Users
• Subsegments:
• 1) By Anthrax-Based Toxins: Anthrax Lethal Toxin; Anthrax Protective Antigen
• 2) By Diphtheria Toxin (DT) And Derivatives: Diphtheria Toxin; DT Fragment-Based Immunotoxins
• 3) By Pseudomonas Exotoxin (PE) And Derivatives: PE38-Based Immunotoxins; PE-Based Fusion Proteins
• 4) By Ribosome Inactivating Proteins-Based Immunotoxins: Ricin-Based Immunotoxins; Gelonin-Based Immunotoxins
• 5) By Ribonucleases-Based Immunotoxins: Onconase-Based Immunotoxins; Binase-Based Immunotoxins
• 6) By Other Types: Shiga Toxin-Based Immunotoxins; Other Toxin-Based Immunotoxins
• Companies Mentioned: Pfizer Inc.; Roche Holding AG; AbbVie Inc.; Bayer AG; Bristol Myers Squibb
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Immunotoxin Market Characteristics

3. Immunotoxin Market Trends And Strategies

4. Immunotoxin Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Immunotoxin Growth Analysis And Strategic Analysis Framework

• 5.1. Global Immunotoxin PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Immunotoxin Market Growth Rate Analysis
• 5.4. Global Immunotoxin Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Immunotoxin Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Immunotoxin Total Addressable Market (TAM)

6. Immunotoxin Market Segmentation

• 6.1. Global Immunotoxin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anthrax Based Toxins
• Diphtheria Toxin (DT) And Derivatives
• Pseudomonas Exotoxin (PE) And Derivatives
• Ribosome Inactivating Proteins Based Immunotoxins
• Ribonucleases-Based Immunotoxins
• Other Types
• 6.2. Global Immunotoxin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Solid Tumors
• Leukemias
• Other Applications
• 6.3. Global Immunotoxin Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Clinics
• Cancer And Radiation Therapy Centers
• Research Labs
• Other End-Users
• 6.4. Global Immunotoxin Market, Sub-Segmentation Of Anthrax-Based Toxins, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anthrax Lethal Toxin
• Anthrax Protective Antigen
• 6.5. Global Immunotoxin Market, Sub-Segmentation Of Diphtheria Toxin (DT) And Derivatives, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diphtheria Toxin
• DT Fragment-Based Immunotoxins
• 6.6. Global Immunotoxin Market, Sub-Segmentation Of Pseudomonas Exotoxin (PE) And Derivatives, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• PE38-Based Immunotoxins
• PE-Based Fusion Proteins
• 6.7. Global Immunotoxin Market, Sub-Segmentation Of Ribosome Inactivating Proteins-Based Immunotoxins, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ricin-Based Immunotoxins
• Gelonin-Based Immunotoxins
• 6.8. Global Immunotoxin Market, Sub-Segmentation Of Ribonucleases-Based Immunotoxins, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Onconase-Based Immunotoxins
• Binase-Based Immunotoxins
• 6.9. Global Immunotoxin Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Shiga Toxin-Based Immunotoxins
• Other Toxin-Based Immunotoxins

7. Immunotoxin Market Regional And Country Analysis

• 7.1. Global Immunotoxin Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Immunotoxin Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Immunotoxin Market

• 8.1. Asia-Pacific Immunotoxin Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Immunotoxin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Immunotoxin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Immunotoxin Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Immunotoxin Market

• 9.1. China Immunotoxin Market Overview
• 9.2. China Immunotoxin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Immunotoxin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Immunotoxin Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Immunotoxin Market

• 10.1. India Immunotoxin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Immunotoxin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Immunotoxin Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Immunotoxin Market

• 11.1. Japan Immunotoxin Market Overview
• 11.2. Japan Immunotoxin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Immunotoxin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Immunotoxin Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Immunotoxin Market

• 12.1. Australia Immunotoxin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Immunotoxin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Immunotoxin Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Immunotoxin Market

• 13.1. Indonesia Immunotoxin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Immunotoxin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Immunotoxin Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Immunotoxin Market

• 14.1. South Korea Immunotoxin Market Overview
• 14.2. South Korea Immunotoxin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Immunotoxin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Immunotoxin Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Immunotoxin Market

• 15.1. Western Europe Immunotoxin Market Overview
• 15.2. Western Europe Immunotoxin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Immunotoxin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Immunotoxin Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Immunotoxin Market

• 16.1. UK Immunotoxin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Immunotoxin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Immunotoxin Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Immunotoxin Market

• 17.1. Germany Immunotoxin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Immunotoxin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Immunotoxin Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Immunotoxin Market

• 18.1. France Immunotoxin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Immunotoxin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Immunotoxin Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Immunotoxin Market

• 19.1. Italy Immunotoxin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Immunotoxin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Immunotoxin Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Immunotoxin Market

• 20.1. Spain Immunotoxin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Immunotoxin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Immunotoxin Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Immunotoxin Market

• 21.1. Eastern Europe Immunotoxin Market Overview
• 21.2. Eastern Europe Immunotoxin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Immunotoxin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Immunotoxin Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Immunotoxin Market

• 22.1. Russia Immunotoxin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Immunotoxin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Immunotoxin Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Immunotoxin Market

• 23.1. North America Immunotoxin Market Overview
• 23.2. North America Immunotoxin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Immunotoxin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Immunotoxin Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Immunotoxin Market

• 24.1. USA Immunotoxin Market Overview
• 24.2. USA Immunotoxin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Immunotoxin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Immunotoxin Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Immunotoxin Market

• 25.1. Canada Immunotoxin Market Overview
• 25.2. Canada Immunotoxin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Immunotoxin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Immunotoxin Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Immunotoxin Market

• 26.1. South America Immunotoxin Market Overview
• 26.2. South America Immunotoxin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Immunotoxin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Immunotoxin Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Immunotoxin Market

• 27.1. Brazil Immunotoxin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Immunotoxin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Immunotoxin Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Immunotoxin Market

• 28.1. Middle East Immunotoxin Market Overview
• 28.2. Middle East Immunotoxin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Immunotoxin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Immunotoxin Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Immunotoxin Market

• 29.1. Africa Immunotoxin Market Overview
• 29.2. Africa Immunotoxin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Immunotoxin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Immunotoxin Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Immunotoxin Market Competitive Landscape And Company Profiles

• 30.1. Immunotoxin Market Competitive Landscape
• 30.2. Immunotoxin Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bristol Myers Squibb Overview, Products and Services, Strategy and Financial Analysis

31. Immunotoxin Market Other Major And Innovative Companies

• 31.1. Thermo Fisher Scientific Inc.
• 31.2. AstraZeneca plc
• 31.3. Merck KGaA
• 31.4. BioNTech SE
• 31.5. Ipsen Pharma
• 31.6. Seagen Inc.
• 31.7. Orion Corporation
• 31.8. GenScript
• 31.9. Cytek Biosciences
• 31.10. MacroGenics Inc.
• 31.11. Sutro Biopharma Inc.
• 31.12. Sorrento Therapeutics Inc.
• 31.13. Innate Pharma Inc.
• 31.14. Cayman Chemical
• 31.15. ImmunoGen Inc.

32. Global Immunotoxin Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Immunotoxin Market

34. Recent Developments In The Immunotoxin Market

35. Immunotoxin Market High Potential Countries, Segments and Strategies

• 35.1 Immunotoxin Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Immunotoxin Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Immunotoxin Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer